The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Minimal Residual Disease in Childhood B-Lineage Lymphoblastic Leukemia: Persistence of Leukemic Cells during the First 18 Months of Treatment
Abstract
BACKGROUND: Whether patients in clinical remission for acute lymphoblastic leukemia (ALL) continue to harbor leukemic cells is not known, because methods of detecting residual malignant cells have not been sufficiently sensitive. This information might be useful for predicting recurrence and determining the duration of therapy. METHODS: Using a sensitive new method--identifying complementarity-determining region III sequences with the polymerase chain reaction--we estimated the number of residual leukemic cells in the bone marrow of eight children with B-lineage lymphoblastic leukemia before and after remission. RESULTS: Induction chemotherapy produced a 3-to-4-log reduction in the number of leukemic cells. In all samples obtained up to 18 months after diagnosis, however, 0.004 to 2.6 percent of bone marrow nucleated cells were residual leukemic cells. Among the four patients studied more than 18 months after diagnosis, three had no detectable leukemic cells in marrow samples. Despite this, one of them, who was no longer receiving therapy, had a central nervous system relapse. In one patient receiving maintenance chemotherapy, there was a 60-fold increase in leukemic cells three months before bone marrow relapse. CONCLUSIONS: The complete disappearance of leukemic cells (or their reduction below our method's threshold of detection, 1 in 100,000 cells) may be necessary to achieve a cure of ALL. The quantification of residual leukemic cells in serial marrow aspirates during therapy may allow the early detection of relapse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase
Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. B., & Erlich, H. A. (1988) · Science · doi:10.1126/science.2448875 · Cited by 17,719
Somatic generation of antibody diversity
Tonegawa, S. (1983) · Nature · doi:10.1038/302575a0 · Cited by 4,005
Cited by
Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia
Cavé, H., van der Werff ten Bosch, J., Suciu, S., Guidal, C., Waterkeyn, C., Otten, J., Bakkus, M., Thielemans, K., Grandchamp, B., Vilmer, E., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390904 · Cited by 768
The clinical pharmacology of 6-mercaptopurine
Lennard, L. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf02220605 · Cited by 647
Ramasamy, I., Brisco, M., & Morley, A. (1992) · Journal of Clinical Pathology · doi:10.1136/jcp.45.9.770 · Cited by 260
Downing, Jr., Head, D., Curcio-Brint, A., Hulshof, M., Motroni, T., Raimondi, S., Carroll, A., Drabkin, H., Willman, C., & Theil, K. (1993) · Blood · doi:10.1182/blood.v81.11.2860.2860 · Cited by 173
Metadata
- Authors
- Yamada, M., Wasserman, R., Lange, B., Reichard, B. A., Womer, R. B., & Rovera, G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1990-08-16
- Volume
- 323
- Issue
- 7
- Pages
- 448-455
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2336893066
- Cited by
- 200
- References
- 2
- FWCI
- 48.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Minimal Residual Disease in Childhood B-Lineage Lymphoblastic Leukemia: Persistence of Leukemic Cells during the First 18 Months of Treatment. https://app.cochat.ai/papers/10.1056/nejm199008163230705
- The paper
- Yamada, M., Wasserman, R., Lange, B., Reichard, B. A., Womer, R. B., & Rovera, G. (1990). Minimal Residual Disease in Childhood B-Lineage Lymphoblastic Leukemia: Persistence of Leukemic Cells during the First 18 Months of Treatment. New England Journal of Medicine. https://doi.org/10.1056/nejm199008163230705
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.